Valuation: Ardelyx, Inc.

Market Cap 832M 739M 690M 629M 1.19B 80.01B 1.2B 8.35B 3.24B 40.9B 3.12B 3.06B 131B P/E 2026 *
-18.6x
P/E 2027 * 14.4x
Enterprise Value 832M 739M 690M 629M 1.19B 80.01B 1.2B 8.35B 3.24B 40.9B 3.12B 3.06B 131B EV / Sales 2026 *
1.7x
EV / Sales 2027 * 1.33x
Free-Float
95.99%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-2.34%
Current month-2.34%
1 month-12.11%
3 months-36.62%
6 months-43.77%
Current year-42.71%
1 week 3.29
Extreme 3.29
3.46
1 month 3.29
Extreme 3.29
3.92
Current year 3.29
Extreme 3.29
8.4
1 year 3.29
Extreme 3.29
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 2009-02-28
Director of Finance/CFO 55 2025-11-03
Chief Tech/Sci/R&D Officer 50 2026-03-31
Director TitleAgeSince
Director/Board Member 61 2009-02-28
Chairman 60 2014-02-28
Director/Board Member 59 2014-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Sell

Chief Financial Officer

-1,558 0.0006%
8/21/26 Sell

Controller/Auditor

-3,982 0.0016%
8/21/26 Sell

Head of Human Resources

-15,136 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-2.34%-36.38%-17.73% 842M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
+0.36%+0.81%+352.17%+689.61% 44.13B
-0.96%-4.50%+26.36%+33.18% 42.91B
-0.20%-0.77%+3.74%+100.60% 40.79B
-0.54%+2.93%+9.31%+50.41% 30.77B
-2.68%+2.92%+29.63%+19.50% 29.31B
+0.05%-1.64%-7.28%-14.06% 24.33B
Average -0.32%-0.54%+45.31%+106.48% 39.39B
Weighted average by Cap. +0.10%-0.74%+58.25%+128.92%

Financials

2026 *2027 *
Net sales 489M 434M 405M 369M 697M 46.99B 703M 4.91B 1.9B 24.02B 1.84B 1.8B 77.09B 624M 554M 517M 472M 889M 59.98B 898M 6.26B 2.43B 30.66B 2.34B 2.29B 98.4B
Net income -44.5M -39.54M -36.9M -33.63M -63.43M -4.28B -64.02M -447M -173M -2.19B -167M -163M -7.02B 62.15M 55.22M 51.54M 46.98M 88.6M 5.97B 89.43M 624M 242M 3.05B 233M 228M 9.8B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
26-10-02 US$3.340 -1.18% 4,092,149
26-10-01 US$3.380 -1.17% 4,107,365
26-09-30 US$3.420 +0.88% 4,412,507
26-09-29 US$3.390 -0.59% 4,434,057
26-09-28 US$3.410 -0.29% 3,318,164
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.340USD
Average target price
12.90USD
Spread / Average Target
+286.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock